Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-08-28
Tempus AI, Inc.
Tempus AI sells genomic diagnostics, clinical workflow software, and data-driven AI tools to oncologists, health systems, and biopharma customers.
ai biotech healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Trusted oncology rails with contingent upside
The core case is a premium diagnostics business compounding into a higher-value oncology operating layer. Upside depends on converting reimbursement wins, MRD scale, and workflow trust into durable cash generation before the AI premium fades.

Analysis

Thesis
Tempus can grow from a premium precision-oncology lab into a trusted execution rail for cancer care: diagnostics create proprietary longitudinal data, that data improves applications, and workflow embedment plus reimbursement wins can shift value capture toward higher-margin actions, not just tests.
Last Economy Alignment
Tempus benefits as AI makes clinical interpretation cheaper because it owns harder-to-copy data rights, regulated diagnostics, and embedded workflow trust; the main offsets are reimbursement, privacy, and integration gates.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.5x (from 5 most recent analyses)
Reasoning
This is a mix-shift compounding story more than a pure test-volume story. Core diagnostics can keep growing, but the real upside comes from MRD, better therapy-selection pricing, and moving data plus workflow into trusted clinical actions. I assume Tempus keeps a premium valuation, but below the very best category leaders, because reimbursement and integration risk should still matter in 2031.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The central risk is permissioned monetization: Tempus must turn real demand into reimbursed pricing, higher-margin data revenue, and trusted workflow actions before its premium valuation compresses. Personalis adds upside but also financing and integration burden, while privacy or reimbursement shocks could weaken the data flywheel that underpins the AI narrative.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.64
It controls the test orders, the results, and the data rights inside cancer workflows, so every new case can make its software and research products smarter. The risk is that reimbursement, privacy rules, or a failed shift from selling tests to selling trusted actions leaves it looking like a lab instead of an AI rail.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$62.64
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case